Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue

Cancer-related fatigue is a common and debilitating late effect in pediatric brain tumor survivors. Currently, evidence-based recommendations to ameliorate this condition are lacking. The researchers will investigate the ability of methylphenidate to improve fatigue and cognition in pediatric brain tumor survivors suffering from cancer-related fatigue. Methylphenidate is a drug (central nervous stimulant) most commonly used in the treatment of hyperkinetic disorders such as attention-deficit/hyperactivity disorder (ADHD). If methylphenidate shows an effect, the prospects are important for th

Trial Details

NCT ID
NCT06905587
Phase
PHASE3
Sponsor
Odense University Hospital
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • Methylphenidate (MPH)
  • Placebo
Locations (sample)
  • Aalborg, Denmark|57.048,9.9187
  • Aarhus, Denmark|56.15674,10.21076
  • Copenhagen, Denmark|55.67594,12.56553
  • Odense, Denmark|55.39594,10.38831

Key Eligibility Criteria

  • Diagnosed and treated for a brain tumor during childhood or adolescence (0-≤18 years).
  • Treated for a PBT during the previous 10 years, starting from date of diagnosis.
  • Aged ≥6 years 0 months at the start of the trial.
  • Off therapy/active treatment for pediatric brain tumor (PBT) for 12 months at the start of the trial.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →